![](https://cdn.sanity.io/images/0vv8moc6/onclive/72302b2d99bfbb93d535f049fbf4f54d8cb085a3-262x145.jpg?fit=crop&auto=format)
Dr Riess on Treatment Developments in ALK+ and ROS1+ NSCLC
Jonathan Wesley Riess, MD, MS, director, Thoracic Oncology, associate professor, medicine, Division of Hematology and Oncology, University of California, Davis Comprehensive Cancer Center, discusses developments in the treatment of patients with non–small …